Clinical trials: Adjuvant Immunotherapy
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Glioblastoma Multiforme
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with…
- Trial name
- NCT04277221
- Testing
- Autologous Dendritic Cell/Tumor Antigen, ADCTA
- Where
- 7 sites in Taiwan
- Volunteers
- 118 people
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Esophageal Squamous Cell Carcinoma Thoracic Stage II, Esophageal Squamous Cell Carcinoma Thoracic Stage III
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Esophageal cancer (EC) is one of the most common malignant tumors of the digestive tract in human beings. Most cases of EC are initially diagnosed in an advanced stage of the disease.
- Conditions
- Esophageal Squamous Cell Carcinoma Thoracic Stage II, Esophageal Squamous Cell Carcinoma Thoracic Stage III, Esophageal Squamous Cell Carcinoma Thoracic Stage IV
- Trial name
- NCT06161909
- Testing
- sintilimab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fujian Medical University Union Hospital
Cutaneous Squamous Cell Carcinoma
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
- Trial name
- MATISSE (NCT04620200)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Resectable/Potentially Resectable NSCLC
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
This is a prospective, observational, multicenter real-world study aiming to investigate the efficacy and safety of NSCLC patients with or without adjuvant immunotherapy who have achieved pathologic complete remission after…
- Trial name
- NCT06243679
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Myeloid Leukemia
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy for haematological malignancies.
- Trial name
- NCT00815321
- Testing
- Autologous CIK cell infusion
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Singapore General Hospital
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Urothelial Cancer
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.
The main objective is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy with durvalumab, to standard neoadjuvant chemotherapy (with cisplatin/gemcitabine) and surgery in urothelial carcinoma could improve…
- Trial name
- SAKK 06/17 (NCT03406650)
- Testing
- Neoadjuvant and adjuvant durvalumab
- Where
- 17 sites in Germany, Switzerland
- Volunteers
- 61 people
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer Stage IV, No Evidence of Disease State
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state.
- Trial name
- VIVA (NCT05382741)
- Testing
- Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules
- Where
- Italy
- Volunteers
- 182 people
- Sponsor
- Ospedale Policlinico San Martino
Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
- Trial name
- NCT07145931
- Testing
- Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Renal Cell
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal…
- Trial name
- NCT00502034
- Testing
- Interferon Alfa-2a, Interleukin-2
- Where
- 8 sites in Italy
- Volunteers
- 310 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC)
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
Postoperative radiotherapy is a conventional treatment for breast cancer patients with a high risk of recurrence, such as those with regional lymph node metastasis, especially TNBC.
- Conditions
- Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
- Trial name
- NCT07046195
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Melanoma
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
Surgical excision is the treatment of choice for stage II, III and resectable stage IV melanoma and is curative in most cases. Given the recent success of immunotherapy for the treatment of patients with advanced metastatic…
- Trial name
- Mel-ImmAdj (NCT05527795)
- Testing
- Frequency and duration of response to adjuvant immunotherapy according to clinical features, Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features, Duration of relapse-free survival according to clinical features
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Small Cell Lung Cancer (SCLC)
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
- Trial name
- NCT07149363
- Testing
- Durvalumab 50 MG/ML
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Alliance Foundation Trials, LLC.
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04267237
- Testing
- Atezolizumab, RO7198457
- Sponsor
- Hoffmann-La Roche
Recurrent Nasopharyngeal Carcinoma
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma
- Trial name
- NCT05350891
- Testing
- endoscopic surgery
- Where
- 8 sites in China
- Volunteers
- 77 people
- Sponsor
- Eye & ENT Hospital of Fudan University